Drug Profile
Liposomal docetaxel - TOT Biopharm
Alternative Names: TID-214Latest Information Update: 25 Apr 2022
Price :
$50
*
At a glance
- Originator TOT Biopharm
- Class Antineoplastics; Taxanes
- Mechanism of Action Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 25 Apr 2022 TID 214 is still in preclinical development in Solid tumours in China
- 28 Nov 2020 No recent reports of development identified for preclinical development in Solid tumours in China
- 20 Oct 2016 Preclinical trials in Solid tumours in China (unspecified route) (TOT Biopharm pipeline, October 2016)